Sort
23,748 grants matching “melanoma”
Administrative Core
$231,514John H Sampson · Duke University · P50 · FY2017 · CA
"Modulation of Immune Checkpoints by Self-Deliverable RNAi for Adoptive Cell Transfer"
$231,500Alexey Wolfson · Advanced Rna Technologies, Llc · R43 · FY2017 · CA
SPECIMAN RESOURCE CORE
$231,493Jennifer McNiff · Yale University · P50 · FY2010 · CA
SPECIMAN RESOURCE CORE
$231,493Jennifer McNiff · Yale University · P50 · FY2008 · CA
SPECIMAN RESOURCE CORE
$231,493Jennifer McNiff · Yale University · P50 · FY2009 · CA
SPECIMAN RESOURCE CORE
$231,492Jennifer McNiff · Yale University · P50 · FY2007 · CA
IDENTIFICATION OF PARALOG DEPENDENCIES AND RESISTANCE MECHANISMS IN MELANOMA
$231,432The Broad Institute, Inc · · FY2019 · Department of the Army
Inflammatory mediators and UV-induced carcinogenesis
$231,431Stephen E Ullrich · University Of Tx Md Anderson Can Ctr · R01 · FY2006 · CA
METALLOPROTEINASE INHIBITORS IN TUMOR PROGRESSION
$231,281Children'S Hospital Los Angeles · R01 · FY2003 · CA
IN SITU ACTIVATION OF ANTITUMOR EFFECTORS
$231,264Univ Of Med/Dent Nj-R W Johnson Med Sch · R01 · FY2000 · CA
Imaging/Histopathology Core
$231,232Linda D Hazlett · Wayne State University · P30 · FY2015 · EY
Dietary methionine restriction as a therapeutic strategy for metastatic melanoma
$231,139Isabelle Racine Miousse · University Of Arkansas At Fayetteville · P20 · FY2021 · GM
Targeting the B Cell Receptor Signaling Network in Lymphoma
$231,136Jonathan Michael Irish · Vanderbilt University · R00 · FY2013 · CA
Multi-peptide Vaccine Administered with Cyclophosphamide for High-risk Melanoma
$231,032Craig Lee Slingluff · University Of Virginia · R01 · FY2009 · CA
Role of PRMT5 in HTLV-1 transformation and disease
$231,000Patrick Lee Green · Ohio State University · R21 · FY2016 · AI
Impact of HIV infection on anti-tumor CD8 responses in vivo
$231,000Dimitrios N Vatakis · University Of California Los Angeles · R21 · FY2014 · AI
Targeting the suppressive immune microenvironment in leptomeningeal melanoma metastases
$230,992Keiran Smalley · H. Lee Moffitt Cancer Ctr & Res Inst · R21 · FY2021 · CA
GENETIC CONTROL OF CELL FATE DIVERSITY IN DROSOPHILA
$230,955Duke University · R01 · FY2000 · GM
Multiscale modeling of leukocyte-tumor cell adhesion to endothelium in shear flow
$230,950Cheng Dong · Pennsylvania State University, The · R01 · FY2008 · CA
Core D: Pathology and BioImaging
$230,920Wiam Bshara · Roswell Park Cancer Institute Corp · P01 · FY2024 · CA
EASTERN COOPERATIVE ONCOLOGY GROUP
$230,875Mayo Clinic Coll Of Medicine, Rochester · U10 · FY2002 · CA
Preclinical Modelling and Therapeutic Development for Other Cancer Indications
$230,821Shyam Sharan · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA
Imaging/Histopathology Core
$230,762Linda D Hazlett · Wayne State University · P30 · FY2014 · EY
Developing Novel NLRX1-Based Immuno-Oncology Therapeutics
$230,729Andrew Leber · Biotherapeutics, Inc. · R43 · FY2020 · CA
Progressive acquisition of novel neural crest derivatives along the neural axis during vertebrate evolution
$230,685Marianne Bronner-Fraser · California Institute Of Technology · R35 · FY2024 · NS